Company intelligence / Profile preview
Bioxyma
Araraquara, São Paulo, Brazilbioxyma.com.br ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Bioxyma is a Brazilian biotechnology company specializing in the development of recombinant proteins and innovative biological therapies. Founded in 2008 and headquartered in Araraquara, São Paulo, the company focuses on high-complexity biopharmaceuticals for oncology, hematology, and infectious diseases. Bioxyma is notably involved in the development of the Spike-N-Benz COVID-19 vaccine in collaboration with the University of São Paulo and other partners. Their portfolio includes biosimilars such as Filgrastim, aimed at treating chemotherapy-induced neutropenia. The company leverages its proprietary protein expression platforms to enhance the accessibility of advanced biologics in the Latin American market.
- Therapeutic areas
- Infectious DiseasesHematologyNeurology
- Modalities
- Recombinant proteinBiologicVaccine
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of São PauloFederal University of Rio de Janeiro
Beyond the preview
Go deeper on Bioxyma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bioxyma.